Received Jun 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | TE499 | — |
Pediarix Administration to an Adult patient; Pediarix Administration to an Adult patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 67-year-old female patient who received DTPa-HBV-IPV (Pediarix) suspension for injection in pre-filled syringe (batch number TE499 with expiry date 02-FEB-2027) for prophylaxis. On 29-MAY-2026, the patient received Pediarix. On 29-MAY-2026, an unknown time after receiving Pediarix, the patient experienced adult use of a child product (Verbatim: Pediarix Administration to an Adult patient) and underdose (Verbatim: Pediarix Administration to an Adult patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 29-MAY-2026 The reporter reported that 67-year-old patient mistakenly received Pediarix. The reporter asked for recommendations on this situation. The batch number was not provided upon follow- up with the reporter.